Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation

Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation.
Extended antiviral curing after a lung move may staff prevent dangerous complications and organ rejection, a new study from Duke University Medical Center shows. A stale cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes passive effects but can be life-threatening for transplant patients. Standard preventive therapy involves taking the cure valganciclovir (Valcyte) for up to three months naturalsuccessusa.com. But even with this treatment, most lung transplant patients forth CMV infections within a year.

The Duke study included 136 patients who completed three months of spoken valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of vocalized valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 rare centers (one faction of which received the additional medication and a control guild that received the placebo, with neither the researchers nor the participants knowing who was in the control group) hamdard. Researchers found that CMV infection occurred in 10 percent of the extended therapy group, compared to 64 percent of the placebo group.

Pneumonia caused by CMV virus occurred in 4 percent of the extended-treatment order and in 32 percent of the placebo group. "We found that 1 year of vocal valganciclovir was extremely striking and led to a dramatic reduction in the rate of CMV infection and disease," Dr Scott Palmer, thorough director of the Lung Transplant Program at Duke University Medical Center, said in a university front-page news release. Potential side effects of valganciclovir include nausea, diarrhea, anemia and other blood disorders, retinal detachment, headache, fever, vomiting, crackers changes and other problems.

However, the sanctum "showed that there was no increased or added toxicity with the extended course of treatment. In addition, the research examined viral resistance mutations and demonstrated that extended therapy did not heroine to increased drug resistance, a potential concern with longer courses of treatment" worldmedexpert.com. The study, published in the June 15 egress of the Annals of Internal Medicine, was funded by Roche Pharmaceuticals, which makes Valcyte.